StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
6062.T$1315.00-1.57%
Fair $1315.00+0.0%

6062.T

Charm Care Corporation

Healthcare / Medical Care FacilitiesTokyo

$1315.00

-21.00 (-1.57%)

Fairly Valued+0.0%Fair Value $1315.00Fund rank 25/100 · Data gapFallback financials|
SA 51/C
F-Score: 3/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 17%

FCF escenarios

weak_data · normalized FCF $-1.1B · quality 41.7/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 15/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

51/100

C

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 6062.TLocal privado en este navegador · Charm Care Corporation
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$43.0B

P/E

13.0x

↓

EV/EBITDA

8.3x

↓

ROE

14.2%

↑

Gross Margin

15.5%

↓

Debt/Equity

0.65

↑
52-Week Range$1315
$1029$1457

TradingView lightweight chart

6062.T price, volumen y niveles de valoración

Último $1,315Periodo +1653.3%
Fair value: $1,315

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+17.1%

FCF CAGR

—

FCF margin

-2.4%

FCF / Net income

-0.38x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $46.67B · net income $2.94B · FCF $-1.11B

2022-FY → 2025-FY

Gross margin

15.5%-0.5% pts

Operating margin

8.2%+0.3% pts

Net margin

6.3%-3.9% pts

FCF margin

-2.4%-7.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$46.67B$46.67B$47.83B$37.89B$29.07B
Net Income$2.94B$2.94B$4.28B$3.21B$2.95B
EBITDA$5.69B$5.69B$7.35B$5.78B$5.38B
EPS89.7789.77130.7998.1090.33
Gross Margin15.5%15.5%17.4%18.0%16.0%
Operating Margin8.2%8.2%11.3%11.1%7.9%
Net Margin6.3%6.3%8.9%8.5%10.2%
Balance Sheet
Debt/Equity0.650.650.580.870.87
Current Ratio1.601.60———
Cash Flow
Free Cash Flow$-1.11B$-1.11B$6.51B$-1.62B$1.34B
Returns
ROE14.2%14.2%22.9%21.2%23.7%
Valuation
P/E12.9912.9912.0713.1011.16
EV/EBITDA8.318.316.778.376.86
P/B2.082.082.762.772.64
Growth & Yield
Revenue Growth-2.4%-2.4%26.2%30.3%—
EPS Growth-31.4%-31.4%33.3%8.6%—
Dividend Yield3.0%3.0%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

9.1%

razonable

EPS terminal req.

$116.68

Spread vs growth

-40.5%

5Y implied EPS CAGR

9.5%

razonable

EPS terminal req.

$141.19

Spread vs growth

-40.8%

10Y implied EPS CAGR

9.7%

razonable

EPS terminal req.

$227.38

Spread vs growth

-41.1%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +10.9%

Total return

+10.9%

Start / end P/E

9.3x → 14.6x

EPS bridge

130.79 → 89.77

Residual

-17.9%

EPS growth-31.4%
Multiple rerating+57.2%
Dividend+3.0%
Residual / FX / buybacks / cross-term-17.9%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.